Immunitrack is proud to co-sponsor the PEGS Summit 2022 in Boston, that brings together scientists and researchers who are at the leading edge of biotherapeutic drug development from academia, biotech, and pharma
Our agenda for the event: Our CSO Sune Justesen will present a talk and will be present at the venue throughout the summit.
Sponsored Presentation: From T cell epitope discovery to MHC/epitope targeted therapeutics, Wednesday May 4th at 10 AM.
The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in manufacturing and studying MHC I and II molecules and their interactions with peptide epitopes. In this presentation we will present our capabilities within the MHC area and how they can be applied as the best starting point for generating MHC/epitope targeted therapeutics.
Reach out for Sune during the event to learn more about Immunitrack and about how we can assist you in targeting immunogenic cancer epitopes for drug discovery projects within immune-oncology.
About The Event
The event is organised by Cambridge Healthtech Institute. You can read more about the event on the organiser’s website here: PEGS BOSTON Conference and EXPO May 2nd- 6th 2022.
The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in manufacturing and studying MHC I and II molecules and their interactions with peptide epitopes. Using our deep knowledge in this area, we have developed the proprietary epitope screening platform technology, NeoScreen. NeoScreen accurately assays the affinity and stability of MHC/epitope interactions, and the technology has the capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immune-oncology, vaccine production, T cell therapies and immune monitoring.
Immunitrack’s mission is to provide the pharmaceutical industry and research community with tailor made technology and reagents to select or redesign drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses.
Immunitrack actively collaborates with some of the leading research groups within immuno-oncology at the Johns Hopkins University Hospital, University of Columbia, Dana Farber Cancer Institute, and the National Center for Cancer Immune Therapy as well as leading pharmaceutical and biotech companies.
Find out more about our latest publications
Find out more about applications of our platform in: